Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Barton asks FDA if internal probe of data release to Summit precludes criminal prosecution.

This article was originally published in The Gray Sheet

Executive Summary

REP. BARTON DETERMINING IF "POSSIBLE CRIMINAL PROSECUTION" FOR FDA DATA RELEASE to Summit Technology has been "jeopardized" by FDA's in-house investigation of the agency's late-November breach of confidentiality. In a May 22 letter to FDA Commissioner David Kessler, Rep. Joe Barton (R-Tex.), chairman of the House Commerce/Oversight Subcommittee, states that "the subcommittee needs to be assured that the conduct of FDA's internal investigation has not jeopardized a possible referral or possible criminal prosecution."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel